David Erritzoe
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
DMT and 5-MeO-DMT induce profound experiences, including encounters with entities and shifts in beliefs. Imperial College London's research investigates these psychedelics' effects on the brain and consciousness for therapeutic insights.
Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.
Roland Griffiths
Ayahuasca, a psychoactive tea from Amazonian plants, shows promise in treating depression and grief. Urban ritual use has grown globally, including in the U.S., for addressing anxiety and depression.
Saleena Subaiya
Ketamine and other psychedelics show promise for psychiatric disorders, but their psychoactive effects complicate masking in trials. A triple-masked trial on 40 patients with depression found surprising results.
Boris D. Heifets
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Ayahuasca shows promise as a treatment for major depression, with a trial indicating significant reduction in symptoms and improvements in physiological systems linked to depression. Research on psychedelics for depression
Nicole Galvão-Coelho
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.